StockData
QIAGEN N.V. logo

QIAGEN N.V. (QGEN) stock

QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$49.56−0.19 (-0.38%)

Close on Nov 18, 2026Market cap $10.75BP/E 25.5Yield 0.50%

Qiagen pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Qiagen's pe ratio was 25.9× on Nov 11, 2026, against 135.8× a year earlier. Over the last 5 years it ranged from 17.8× to 145.1×, with a median of 26.0×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202625.9×−102.0
2025Dec 31, 2025127.9×+97.9
2024Dec 31, 202430.1×+5.2
2023Dec 29, 202324.8×+1.1
2022Dec 30, 202223.8×−14.5
2021Dec 31, 202138.2×−7.8
2020Feb 28, 202046.1×+2.7
2019Dec 31, 201943.4×−169.9
2018Dec 31, 2018213.3×+117.5
2017Dec 29, 201795.8×+42.1
2016Dec 30, 201653.6×−7.0
2015Dec 31, 201560.6×−24.5
2014Dec 31, 201485.1×+38.7
2013Dec 31, 201346.4×−1.4
2012Dec 31, 201247.8×+23.5
2011Dec 30, 201124.2×−7.9
2010Dec 31, 201032.2×−21.3
2009Dec 31, 200953.4×–

More Qiagen figures

See a number that looks wrong?